Comparison
CJC-1295 vs Testosterone
Side-by-side of CJC-1295 and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | CJC-1295 | Testosterone |
|---|---|---|
| Category | peptide | hormone |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 168 | 192 |
| Typical dose (mg) ↗ | 0.1 | 150 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | subcutaneous | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 3 | 72 |
| Molecular weight | 3367.83 | 288.42 |
| Molecular formula | C152H252N44O42 | C19H28O2 |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Schedule III controlled substance (US); WADA banned |
| WADA status | banned | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Schedule III |
| Pregnancy | Insufficient data; not recommended | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 446262-90-4 | 58-22-0 |
| PubChem CID | 91971820 | 6013 |
| Wikidata | Q5012154 | Q150726 |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
Edge case: If you cannot self-administer injections, Testosterone is the only oral option in this pair.
Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Testosterone?
CJC-1295 and Testosterone differ in category (peptide vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Testosterone?
CJC-1295 half-life is 168 hours; Testosterone half-life is 192 hours.
Can you stack CJC-1295 with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper